Business

New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease

Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restorationNEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and

articleAnavex Life Sciences Corp.March 20, 20265/company/anavex-life-sciences-corp/news/new-scientific-findings-highlight-hypothesis-of-autophagy-failure-as-a-precursor-of-amyloid-beta-and-tau-pathology-in-alzheimers-disease
New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease

About this update from Anavex Life Sciences Corp.

[{"type":"image","alt":"Anavex Life Sciences Corp.","displaySize":"","headline":null,"caption":"Anavex Life Sciences Corp.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/c04acbca5a62a2d4b04d7751547db9de"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/SJmIQvM5kd6wArAyMSLhjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/c04acbca5a62a2d4b04d7751547db9de","width":300,"height":61},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/SJmIQvM5kd6wArAyMSLhjQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTg1/https://media.zenfs.com/en/globenewswire.com/c04acbca5a62a2d4b04d7751547db9de","width":300,"height":61}},"lazy":false},{"type":"text","content":"Findings underpin potential of Anavex’ lead candidate blarcamesine through its upstream mechanism of action and SIGMAR1-mediated autophagy restoration","length":150,"tagName":"p"},{"type":"text","content":"NEW YORK, March 20, 2026 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that a new peer-reviewed study published by University of California in Proceedings of the National Academy of Sciences, Nexus1 (Shoff et al., 2026) supports the hypothesis that disruption of neuronal homeostasis—particularly autophagy impairment—acts upstream of amyloid beta (Aβ) and tau pathology in Alzheimer’s disease.","length":749,"tagName":"p"},{"type":"text","content":"The publication, titled “The microtubule nexus linking amyloid beta and tau: A simple and unifying theory for the underlying cause of Alzheimer’s disease,” proposes a unified mechanistic framework in which Aβ competitively disrupts tau’s interaction with microtubules, leading to microtubule instability, abnormal tau phosphorylation, and subsequent aggregation.","length":362,"tagName":"p"},{"type":"text","content":"The authors note that autophagy failure associated with aging increases intracellular Aβ levels, directly contributing to the pathological cascade. The publication concludes that pathology be...

More updates from Anavex Life Sciences Corp.

Alzheimer's diseaseAnavex Life Sciences Corp.Parkinson's diseaseRett syndromecentral nervous systemamyloid betabiopharmaceutical companypublicationtau phosphorylationAlzheimer’s pathologyamyloid plaquesautophagy